Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

Jonathan W. Riess, David R. Gandara, Sukhmani K. Padda et al.|Journal of Clinical Oncology|2022

Cited by 12